Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FGEN NASDAQ:NRXP NASDAQ:STTK NASDAQ:TXMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFGENFibroGen$11.84-1.6%$9.08$4.50▼$21.94$47.88M0.7678,831 shs15,459 shsNRXPNRx Pharmaceuticals$3.00+7.1%$2.79$1.10▼$6.01$59.43M1.63506,882 shs662,573 shsSTTKShattuck Labs$1.79-6.8%$1.00$0.69▼$3.95$85.74M1.64934,925 shs327,172 shsTXMDTherapeuticsMD$1.08-2.7%$1.13$0.70▼$2.44$12.50M0.51220,024 shs20,581 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFGENFibroGen0.00%-0.58%+26.77%+80.83%+2.38%NRXPNRx Pharmaceuticals0.00%+1.82%-3.11%-19.54%+62.79%STTKShattuck Labs0.00%+23.87%+92.00%+92.00%-49.61%TXMDTherapeuticsMD0.00%+2.78%-5.12%+2.78%-37.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFGENFibroGen$11.84-1.6%$9.08$4.50▼$21.94$47.88M0.7678,831 shs15,459 shsNRXPNRx Pharmaceuticals$3.00+7.1%$2.79$1.10▼$6.01$59.43M1.63506,882 shs662,573 shsSTTKShattuck Labs$1.79-6.8%$1.00$0.69▼$3.95$85.74M1.64934,925 shs327,172 shsTXMDTherapeuticsMD$1.08-2.7%$1.13$0.70▼$2.44$12.50M0.51220,024 shs20,581 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFGENFibroGen0.00%-0.58%+26.77%+80.83%+2.38%NRXPNRx Pharmaceuticals0.00%+1.82%-3.11%-19.54%+62.79%STTKShattuck Labs0.00%+23.87%+92.00%+92.00%-49.61%TXMDTherapeuticsMD0.00%+2.78%-5.12%+2.78%-37.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFGENFibroGen 2.50Moderate Buy$43.00263.18% UpsideNRXPNRx Pharmaceuticals 3.00Buy$34.501,050.00% UpsideSTTKShattuck Labs 2.86Moderate Buy$4.00123.46% UpsideTXMDTherapeuticsMD 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TXMD, FGEN, STTK, and NRXP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025NRXPNRx PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/8/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.009/8/2025NRXPNRx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/8/2025STTKShattuck LabsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$4.008/25/2025NRXPNRx PharmaceuticalsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/19/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.008/14/2025STTKShattuck LabsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$4.00 ➝ $2.008/14/2025STTKShattuck LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold8/11/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.008/7/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$43.008/4/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFGENFibroGen$7.35M6.52N/AN/A($50.89) per share-0.23NRXPNRx PharmaceuticalsN/AN/AN/AN/A($1.48) per shareN/ASTTKShattuck Labs$5.72M14.99N/AN/A$1.67 per share1.07TXMDTherapeuticsMD$1.76M7.10N/AN/A$2.37 per share0.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFGENFibroGen-$47.58M-$0.38N/AN/AN/A-3.86%N/A-27.34%11/11/2025 (Estimated)NRXPNRx Pharmaceuticals-$25.13M-$2.24N/AN/AN/AN/AN/A-550.94%11/13/2025 (Estimated)STTKShattuck Labs-$75.41M-$1.21N/AN/AN/AN/A-81.80%-71.46%11/13/2025 (Estimated)TXMDTherapeuticsMD-$2.18MN/A0.00∞N/A-17.94%-2.01%-1.40%11/10/2025 (Estimated)Latest TXMD, FGEN, STTK, and NRXP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025NRXPNRx Pharmaceuticals-$0.31-$0.98-$0.67-$0.98N/AN/A8/14/2025Q2 2025STTKShattuck Labs-$0.25-$0.24+$0.01-$0.24N/AN/A8/12/2025Q2 2025TXMDTherapeuticsMDN/A$0.05N/A$0.05N/A$0.95 million8/11/2025Q2 2025FGENFibroGen-$2.25-$3.38-$1.13-$1.88$2.88 million$1.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFGENFibroGenN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ATXMDTherapeuticsMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFGENFibroGenN/A1.041.02NRXPNRx PharmaceuticalsN/A0.110.11STTKShattuck LabsN/A10.2510.25TXMDTherapeuticsMDN/A2.892.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFGENFibroGen72.71%NRXPNRx Pharmaceuticals4.27%STTKShattuck Labs58.74%TXMDTherapeuticsMD30.74%Insider OwnershipCompanyInsider OwnershipFGENFibroGen3.07%NRXPNRx Pharmaceuticals19.00%STTKShattuck Labs12.00%TXMDTherapeuticsMD2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFGENFibroGen5704.04 million3.96 millionOptionableNRXPNRx Pharmaceuticals219.81 million16.05 millionOptionableSTTKShattuck Labs10047.90 million42.16 millionOptionableTXMDTherapeuticsMD42011.57 million11.31 millionOptionableTXMD, FGEN, STTK, and NRXP HeadlinesRecent News About These CompaniesTherapeuticsMD Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comTherapeuticsMD: Q2 Earnings SnapshotAugust 12, 2025 | finance.yahoo.comTherapeuticsMD Announces Second Quarter 2025 Financial ResultsAugust 12, 2025 | businesswire.comTherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gainsJuly 16, 2025 | marketwatch.comMarlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street JournalJune 29, 2025 | wsj.comMayne Pharma Files Legal Complaint Against TherapeuticsMDJune 1, 2025 | tipranks.comTherapeuticsMD Announces First Quarter 2025 Financial ResultsMay 13, 2025 | businesswire.comTherapeuticsMD Inc. stock rises Monday, still underperforms marketMay 12, 2025 | marketwatch.comTherapeuticsMD Inc. stock outperforms competitors despite losses on the dayApril 8, 2025 | marketwatch.comTherapeuticsMD Announces Full Year 2024 Financial ResultsMarch 27, 2025 | businesswire.comTherapeuticsMD, Inc. (TXMD) Latest Press Releases & Corporate News - Yahoo FinanceMarch 26, 2025 | finance.yahoo.comTherapeuticsMD Inc’s Stock Drama: Could This Be a Game-Changer for TXMD Investors?January 7, 2025 | bovnews.comBTherapeuticsMD Inc (TXMD) Stock: A Deeper Look at Its True PotentialJanuary 3, 2025 | bovnews.comBTherapeuticsMD Inc. stock remains steady Friday, still outperforms marketDecember 27, 2024 | marketwatch.comTherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gainsNovember 23, 2024 | marketwatch.comTherapeuticsMD Shifts Focus with Lower Q3 LossesNovember 14, 2024 | markets.businessinsider.comTherapeuticsMD Reports Reduced Losses Amid Strategic ShiftNovember 14, 2024 | markets.businessinsider.comTherapeuticsMD Announces Third Quarter 2024 Financial ResultsNovember 13, 2024 | finance.yahoo.comTherapeuticsMD Inc. stock remains steady Monday, underperforms marketNovember 12, 2024 | marketwatch.comTherapeuticsMD (NASDAQ:TXMD) Stock, Option ChainNovember 6, 2024 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTXMD, FGEN, STTK, and NRXP Company DescriptionsFibroGen NASDAQ:FGEN$11.84 -0.19 (-1.58%) Closing price 04:00 PM EasternExtended Trading$12.00 +0.16 (+1.35%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.NRx Pharmaceuticals NASDAQ:NRXP$3.00 +0.20 (+7.14%) Closing price 04:00 PM EasternExtended Trading$3.05 +0.05 (+1.80%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.Shattuck Labs NASDAQ:STTK$1.79 -0.13 (-6.77%) Closing price 04:00 PM EasternExtended Trading$1.82 +0.03 (+1.96%) As of 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.TherapeuticsMD NASDAQ:TXMD$1.08 -0.03 (-2.67%) Closing price 04:00 PM EasternExtended Trading$1.09 +0.01 (+1.02%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
